|N-(3-((4aS,7aS)-2-氨基-4a,5,7,7a-四氢-4H-呋喃并[3,4-d][1,3]噻嗪-7a-基)-4-氟苯基)-5-氟吡啶甲酰胺盐酸盐|CsnPharm

CAS No.: 1262036-49-6

Synonyms: LY2886721 hydrochloride

LY 2886721 hydrochloride is the first oral inhibitor of human β-secretase (BACE-1) with the potential to treat Alzheimer's Disease.

规格	价格	促销价格	库存	数量

400-920-2911

加入购物车大规格询价

产品咨询

400-920-2911

纯度 & 质量文件批次:

生物活性

描述BACE1, also known as β-secretase, is an aspartyl protease that controls the formation of amyloid β, a peptide crucial for the pathogenesis of Alzheimer's disease. LY2886721 is a potent BACE1 inhibitor with an IC50 value of 20.3±10.1nM. It also exhibits inhibitory activity against human BACE2, a closely related aspartyl protease, with an IC50 value of 10.2±4.8nM. Overnight treatment of HEK293Swe cells with increasing concentrations of LY2886721 led to a dose-dependent decrease in the amount of amyloid β secreted into the medium. The EC50 values for the inhibition of amyloid β_1-40 and amyloid β_1-42 were 18.5nM and 19.7nM, respectively. Overnight exposure of mouse neuronal cultures with increasing concentrations of LY2886721 also dose-dependently decreased the production of amyloid β with an EC50 value of ~10nM. In PDAPP mice, oral administration of LY2886721 at 3, 10, and 30mg/kg significantly reduced hippocampal and cortical levels of amyloid β_1-x compared with the vehicle-treated group. Mice administered with LY2886721 showed reduced brain parenchymal levels of C99 (at 10 and 30mg/kg) and sAPPβ (at 3, 10, and 30mg/kg) compared to the control group.^[1]
作用机制LY2886721 is a BACE1 active site inhibitor with selectivity against cathepsin D, pepsin, and renin.^[1]
参考文献

实验方案

技术信息

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

请登录您的专属账户